UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

CEREVEL THERAPEUTICS HOLDINGS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

15678U 128

(CUSIP Number)

Margaret M. Madden, Esq.

Senior Vice President and Corporate Secretary,

Chief Governance Counsel

Pfizer Inc.

235 East 42nd Street

New York, New York 10017

(212) 733-2323

Copy to

DLA Piper LLP (US)

The Marbury Building

6225 Smith Ave

Baltimore, MD 21209-3600

(410) 580-3000

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

July 1, 2021

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 15678U 128

1Names of Reporting Persons

Pfizer Inc. ( Pfizer )

2CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)

(b) x

3SEC USE ONLY

4SOURCE OF FUNDS

OO

5CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

6CITIZENSHIP OR PLACE OF ORGANIZATION

DELAWARE

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH 7SOLE VOTING POWER

27,349,211(1)

8SHARED VOTING POWER

9SOLE DISPOSITIVE POWER

27,349,211

10SHARED DISPOSITIVE POWER

11AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

27,349,211(1)

12CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

19.4%(1)

14TYPE OF REPORTING PERSON

CO

(1) Based on 141,325,116 shares of common stock, par value $0.0001 per share (the Common Stock ), reported as outstanding in the Prospectus, dated July 1, 2021, filed with the U.S. Securities and Exchange Commission on July 2, 2021 (Registration No. 333-257505) relating to a firm commitment underwritten offering of 14,000,000 shares of Common Stock (the Offering ). The decrease in the percentage of shares of Common Stock held by Reporting Person reported on this Amendment No. 1 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer after giving effect to the Offering.

CUSIP No. 15678U 128

Item. 1. Security and Issuer

This Amendment No. 1 (this Amendment No. 1 ) to the statement on schedule 13D (the Statement ) relates to the common stock, par value $0.0001 per share (the Common Stock ), of Cerevel Therapeutics Holdings, Inc., a Delaware corporation (the Issuer ). The Issuer s principal executive offices are located at 131 Dartmouth Street, Suite 502, Boston, Massachusetts 02116. The Issuer s shares of Common Stock are listed on The Nasdaq Capital Market under the ticker symbol CERE .

Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Statement. Capitalized terms used but not otherwise defined in this Amendment No. 1 shall have the meanings ascribed to them in the Statement.

Item. 5. Interest in Securities of the Issuer

The following amends and restates the information set forth in the paragraphs captioned (a)-(b) of Item 5 of the Statement in their entirety

(a) (b) As of the date the Amendment No. 1, the Reporting Person holds 27,349,211 shares of Common Stock, representing approximately 19.4% of the outstanding shares of Common Stock. The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on 141,325,116 shares of Common Stock issued and outstanding as of July 1, 2021, as reported by the Issuer in the Prospectus, dated July 1, 2021, filed with the U.S. Securities and Exchange Commission on July 2, 2021 (Registration No. 333-257505) (the Prospectus ) relating to a firm commitment underwritten offering of 14,000,000 shares of Common Stock (the Offering ). The decrease in the percentage of shares of Common Stock held by Reporting Person reported on this Amendment No. 1 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer after giving effect to the Offering.

As a result of the voting arrangements described under Item 6 of the Statement, the Reporting Person and BC Perception Holdings, LP ( BC Perception ) may be deemed to be a group for purposes of Section 13(d) under the Securities Exchange Act of 1934, as amended. Based on publicly available information as of the date of the Amendment No. 1, BC Perception owns 60,300,063 shares of Common Stock, or approximately 42.7% of the outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the shares of Common Stock held by BC Perception.

Item. 6. Contracts, Arrangements, Understandings or Relationships with respect to Securities of the Issuer

The following amends the information set forth in Item 6 of the Statement by adding the following paragraph at the end of Item 6

In accordance with the Registration and Shareholder Rights Agreement, the Reporting Person entered into a Lock-Up Agreement with J.P. Morgan Securities LLC, Goldman Sachs Co. LLC, Jefferies LLC and Stifel, Nicolaus Company, Incorporated, book-running managers of the Offering and representatives of the underwriters, pursuant to which the Reporting Person agreed not transfer any securities of the Issuer for 90 days following the date of the Prospectus, subject to certain customary exceptions.

CUSIP No. 15678U 128

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date July 9, 2021Pfizer Inc.

By s Susan Grant

Name Susan Grant

Title Assistant Secretary